Precigen
Company Snapshot
Company Overview
Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases.
In 2015, Intrexon purchased Oxitec, a maker of gene drive technology for $160 million. In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia. In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing
Financial Highlights (FY 2025)
This information is available for BCC Research members only.
Precigen In News
Company's Business Segments
- Biopharmaceuticals : This segment comprises the company's legal entities, Precigen and ActoBio, and royalty interests in therapeutics and therapeutic platforms from companies not controlled by it.
- Exemplar : This segment includes Exemplar Genetics LLC, doing business as Precigen Exemplar, or Exemplar, our wholly owned subsidiary, focused on developing research models and services for healthcare research applications.
Applications/End User Industries
- Biopharmaceutical
- Healthcare
- Life Sciences